Registration open for: 📍#RENALC24 🗓️26 Nov 📍#BLADDR24 🗓️27-28 Nov 📍#PROSCA24 🗓️ 29-30 Nov 🇦🇹Vienna, Austria & online 🌐register here: prosca-bladdr.org/global-forum-o…

Join us for fantastic meeting in Vienna on practical data applications in GU cancers! Giannis Mountzios Marinos Tsiatas Marita Lykka MD MikaLion Ζenia Saridaki Enrique Grande Daniel Castellano Bernadett Szabados Uromigos Ursula Vogl Badrinath Konety, MD, MBA Vadim Koshkin MD silke gillessen OncoAlert Myrto K. Moutafi ANASTASIOS KYRIAZOGLOU

Out commentary on the updated results of DestinyBreast03 is out on @practiceupdate Elsevier T-DXd ⬆️ PFS of 4 times compared to T-DM1 and ⬆️ OS of ~10months These results confirm its role as standard of care in 2️⃣line OncoAlert Michail ignatiadis practiceupdate.com/content/long-t…

All Biochemical Recurrences Are Equal, but Some Are More Equal than Others sciencedirect.com/science/articl… A honor to comment on the superb review by Adam B. Weiner, MD Vérane Achard European Urology

New in #practicalRO: External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline. #radonc bit.ly/alcorn2

Just published in #ASCOEdBook: Mitigating adverse effects of androgen-deprivation therapy ➡️ brnw.ch/21wKIFq #pcsm #ASCO24 #gucsm

Do you want to learn more about histological subtypes of (N)MIBC on a patient case level? ✅ check out our accredited #CME course on this topic ✅ see what your peers and a panel of experts would recommend for a specific patient 🌐 ppcp.mirrorsmed.org/en/topic/9q5t7… @evacomperat

The CAPItello-290 Phase III trial for capivasertib + paclitaxel mTNBC did not meet the dual primary endpoints of improvement in OS vs. pacli + placebo in either the overall population or in pts with PIK3CA, AKT1 or PTEN alterations OncoAlert astrazeneca.com/media-centre/p…

Get up to date with the management of non-metastatic #CRPC 🌐 ppcp.mirrorsmed.org/en/topic/5mdrs… 🎯 Case-based learning 🎯 time-efficient 🎯 accredited 🎯 see expert panel recommendations 🎯 summary of available evidence OncoAlert #prostatecancer

Now out the final outcome analysis from TUXEDO-1 trial T-DXd in patients with active brain metastases 🧠 produced prolonged intra and extra cranial disease control With 26.5 months median follow-up, mPFS was 21 months and mOS not reached OncoAlert academic.oup.com/neuro-oncology…

Interesting thread on Her2 low / ultralow #BreastCancer #bcsm

Our paper is out! Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial | Journal of Clinical Oncology @GBG_Forschung ABCSG Karolinska Institutet #breastcancer ascopubs.org/doi/10.1200/JC…

Long-term results of ATEMPT study published Journal of Clinical Oncology 🚩Adjuvant T-DM1 results in 5-yr iDFS rates of 97.0% for stage 1 HER2+ #breastcancer 🚩APT (paclitaxel+trastuzumab) remains SOC for these patients 💡Want to learn more about HER2+ EBC on a case-based level? Check out our

❓Get more insight in cardiovascular events and ARPI? 👉During #PROSCA24 Suma Konety will give an update lecture on the CV complications related to hormonal therapy 📌Check out our programme: bit.ly/4cluIvT 🗓️ 29-30 Nov, Vienna OncoAlert #prostatecancer #pcsm

Drug-induced ILD is seen with ADCs like T-DXd, a drug used for the management of HER2+ #breastcancer ➡️ See our 🆓 patient cases and EACCME-accredited course on HER2+ MBC: bit.ly/3WS2a8y OncoAlert #bcsm

📌 Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases 🧠: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) | Breast Cancer link.springer.com/article/10.100…

Trastuzumab deturuxtecan has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of unresectable or metastatic hormone receptor positive HER2 low or HER2 ultralow (IHC >0 <1+) breast cancer patients who never received CT according to DESTINY 06 study

The results of SONIA are out on nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s4158…

The interim-analysis of the groundbreaking EUROPA trial demonstrates what we all have been thinking: ⁃Much less AE’s in the RT arm ⁃Better HRQoL preservation in the RT arm Time for a paradigm shift! Congratulations Icro Meattini #SABCS24

Single-modality endocrine therapy versus #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #BreastCancer (EUROPA) The Lancet Oncology ▶️ Share Link – 50 days' free access to the article (Jan 31, 2025): authors.elsevier.com/a/1kFkd5EIIgPe…